Autologous stem cell transplant for poor prognosis lymphoma

Gulati, Subhash C.; Shank, Brenda; Straus, David J.; Koziner, Benjamín; Lee, B.; Mertelsmann, Roland; Dinsmore, Robert E.; Gee, Timothy; Vega, R.; Yopp, Justin M.; O’Reilly, Richard J.; Clarkson, Bayard D.

doi:10.1007/978-1-4613-2607-6_54

Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances 1985

DOI: 10.1007/978-1-4613-2607-6_54

|View full text |Cite

Autologous stem cell transplant for poor prognosis lymphoma

Subhash C. Gulati

Brenda Shank

David J. Straus

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1986

1991

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, contamination of the graft with neoplastic cells is a major problem when performing autologous BMT and a variety of immunologic (12-15) and pharmacological (16, 17) methods have been utilized to eliminate neoplastic cells remaining in marrow. 4-HC, a cyclophosphamide analogue, and VP-16, a semisynthetic congener of podophyllotoxin, were reported to be effective for the in-vitro purging of leukemia and lymphoma cells (16-23), and clinical trials utilizing 4-HC, and VP-16 to purge BM are in progress (24,25). We summarize our experience with various purging methods for MM (26-29).…”

mentioning

confidence: 99%

Ex vivo treatment of myeloma cells by 4‐HC, VP‐16, LAK cells and antibodies

Gulati

Shimazaki

Lemoli

et al. 1989

European J of Haematology

View full text Add to dashboard Cite

To assess the usefulness of 4‐hydroperoxycyclophosphamide (4‐HC) and Etoposide (VP‐16) as a purging agent for myeloma cells in bone marrow ex‐vivo, myeloma cell lines (SK‐RCS‐1, RPMI‐8226), lymphoma cell line (SK‐DHL‐2) and normal bone marrow (BM) cells were treated at different concentrations of 4‐HC, VP‐16. In separate experiments, LAK cells or antibodies were also used to treat the above cell lines. Clonogenic tumor cells from all three cell lines could be reduced by more than 4 logs, when treated alone or as a mixture with irradiated normal bone marrow cells at a 4‐HC concentration of 60 μmol/l. Under similar conditions, approximately 1% of normal BM myeloid progenitor granulocyte‐macrophage colony forming cells (CFU‐GM) survived. The results with LAK cells and antibodies were also encouraging. These observations support the use of various purging methods for myeloma cells for autologous bone marrow transplantation.

show abstract

mentioning

confidence: 99%

Ex vivo treatment of myeloma cells by 4‐HC, VP‐16, LAK cells and antibodies

Gulati

Shimazaki

Lemoli

et al. 1989

European J of Haematology

View full text Add to dashboard Cite

show abstract

L-20 protocol for adult patients (pts) with acute lymphoblastic leukemia (ALL): A protocol utilizing prognostic factors, intensive chemotherapy and autologous “purged” marrow transplantation to eradicate minimal residual disease

1986

View full text Add to dashboard Cite

Parma international protocol: pilot study of DHAP followed by involved- field radiotherapy and BEAC with autologous bone marrow transplantation

Philip

Chauvin

Armitage

et al. 1991

Blood

View full text Add to dashboard Cite

Fifty patients with intermediate- or high-grade non-Hodgkin's lymphoma (NHL) who had relapsed after a complete remission induced by an Adriamycin-containing chemotherapy regimen participated in this prospective pilot study. The patients ranged in age from 16 to 60 years (median 42 years). All patients received dexamethasone, high-dose cytarabine, and cisplatin (DHAP) for two courses at 3- to 4-week intervals. Patients achieving a partial or complete response were scheduled to receive involved-field radiotherapy and high-dose carmustine, etoposide, cytarabine, and cyclophosphamide (BEAC), followed by autologous bone marrow transplantation (ABMT). Among 48 evaluable patients (ie, 1 was lost to follow-up and 1 had no measurable disease) 7 patients obtained a complete response (CR) and another 21 patients achieved partial response (PR), whereas the remaining 20 patients failed. One responder died of treatment-related toxicity, and six others declined ABMT. The patient with no measurable disease did not progress on DHAP and was submitted to ABMT. Twenty-two patients underwent ABMT [20 with BEAC and 2 with cyclophosphamide plus total body irradiation (TBI)] of whom 2 (9%) died of toxicity and 10 relapsed. One patient was a suicide at 28 months post-ABMT in CCR and 9 are alive disease-free 24 months to 32 months (median 30 months) post- ABMT. The actuarial 2-year event-free survival for patients undergoing transplantation is 40%. This prospective multicenter trial documents the ability of DHAP followed by ABMT to produce durable complete remission in a significant proportion of patients with relapsed aggressive NHL. Forty-four percent of all patients with relapsed lymphoma who entered the study actually underwent ABMT and 20% of the total group are projected to be long-term disease-free survivors.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Autologous stem cell transplant for poor prognosis lymphoma

Cited by 3 publications

References 17 publications

Ex vivo treatment of myeloma cells by 4‐HC, VP‐16, LAK cells and antibodies

Ex vivo treatment of myeloma cells by 4‐HC, VP‐16, LAK cells and antibodies

L-20 protocol for adult patients (pts) with acute lymphoblastic leukemia (ALL): A protocol utilizing prognostic factors, intensive chemotherapy and autologous “purged” marrow transplantation to eradicate minimal residual disease

Parma international protocol: pilot study of DHAP followed by involved- field radiotherapy and BEAC with autologous bone marrow transplantation

Contact Info

Product

Resources

About